Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept
OBJECTIVES: Carbamylation is an irreversible post-translational modification of proteins. The presence of anti-carbamylated protein antibodies (anti-CarP) has been observed in rheumatoid arthritis (RA). This study was focused to verify whether anti-CarP antibodies can be used as a predictive factor of clinical response to abatacept (CTLA4-Ig) in RA patients.
METHODS: Sixty RA patients treated with abatacept were enrolled. A home-made ELISA for anti-CarP and a commercial anti-CCP3.1 kit for anti-citrullinated proteins antibodies (anti-CCP) were applied to determine serum levels every six months of therapy. Rheumatoid factor (RF) was also tested.
RESULTS: Anti-CarP positive patients (n=18) were younger (p=0.01) and with a longer disease duration (p=0.05) when compared to anti-CarP negative patients (n=42) at baseline. Considering the entire cohort, a significant reduction of anti-CarP titre after twelve-months of treatment was shown (p<0.01). A significant reduction of Disease Activity Score (DAS) 28-C-reactive protein (CRP) in the first six months of therapy was found in the subgroup of anti-CarP positive patients in comparison with the negative ones (p=0.003). No significant results were found by dividing the cohort using the positivity to anti-CCP and/or RF.
CONCLUSIONS: Earlier onset and a longer disease duration in anti-CarP positive patients might suggest they are specific risk factors for RA in this subgroup of patients. The correlation between the anti-CarP positivity at baseline and the reduction of disease activity during the first six months of treatment with abatacept allowed us to hypothesise that anti-CarP antibodies, but not anti-CCP and/or RF, could be used as a good clinical response predictor.
| Errataetall: |
CommentIn: Clin Exp Rheumatol. 2021 Sep-Oct;39(5):1142-1143. - PMID 33666163 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Clinical and experimental rheumatology - 39(2021), 1 vom: 15. Jan., Seite 91-97 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar, Rajesh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7D0YB67S97 |
|---|
| Anmerkungen: |
Date Completed 10.02.2021 Date Revised 23.09.2022 published: Print-Electronic CommentIn: Clin Exp Rheumatol. 2021 Sep-Oct;39(5):1142-1143. - PMID 33666163 Citation Status MEDLINE |
|---|
| doi: |
10.55563/clinexprheumatol/g8xqxr |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309426510 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309426510 | ||
| 003 | DE-627 | ||
| 005 | 20231225133902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.55563/clinexprheumatol/g8xqxr |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM309426510 | ||
| 035 | |a (NLM)32359037 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kumar, Rajesh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2021 | ||
| 500 | |a Date Revised 23.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Clin Exp Rheumatol. 2021 Sep-Oct;39(5):1142-1143. - PMID 33666163 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Carbamylation is an irreversible post-translational modification of proteins. The presence of anti-carbamylated protein antibodies (anti-CarP) has been observed in rheumatoid arthritis (RA). This study was focused to verify whether anti-CarP antibodies can be used as a predictive factor of clinical response to abatacept (CTLA4-Ig) in RA patients | ||
| 520 | |a METHODS: Sixty RA patients treated with abatacept were enrolled. A home-made ELISA for anti-CarP and a commercial anti-CCP3.1 kit for anti-citrullinated proteins antibodies (anti-CCP) were applied to determine serum levels every six months of therapy. Rheumatoid factor (RF) was also tested | ||
| 520 | |a RESULTS: Anti-CarP positive patients (n=18) were younger (p=0.01) and with a longer disease duration (p=0.05) when compared to anti-CarP negative patients (n=42) at baseline. Considering the entire cohort, a significant reduction of anti-CarP titre after twelve-months of treatment was shown (p<0.01). A significant reduction of Disease Activity Score (DAS) 28-C-reactive protein (CRP) in the first six months of therapy was found in the subgroup of anti-CarP positive patients in comparison with the negative ones (p=0.003). No significant results were found by dividing the cohort using the positivity to anti-CCP and/or RF | ||
| 520 | |a CONCLUSIONS: Earlier onset and a longer disease duration in anti-CarP positive patients might suggest they are specific risk factors for RA in this subgroup of patients. The correlation between the anti-CarP positivity at baseline and the reduction of disease activity during the first six months of treatment with abatacept allowed us to hypothesise that anti-CarP antibodies, but not anti-CCP and/or RF, could be used as a good clinical response predictor | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Peptides, Cyclic |2 NLM | |
| 650 | 7 | |a Abatacept |2 NLM | |
| 650 | 7 | |a 7D0YB67S97 |2 NLM | |
| 650 | 7 | |a Rheumatoid Factor |2 NLM | |
| 650 | 7 | |a 9009-79-4 |2 NLM | |
| 700 | 1 | |a Piantoni, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Boldini, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Garrafa, Emirena |e verfasserin |4 aut | |
| 700 | 1 | |a Bazzani, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Fredi, Micaela |e verfasserin |4 aut | |
| 700 | 1 | |a Ottaviani, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Cavazzana, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Tincani, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Franceschini, Franco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental rheumatology |d 1989 |g 39(2021), 1 vom: 15. Jan., Seite 91-97 |w (DE-627)NLM012613010 |x 0392-856X |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2021 |g number:1 |g day:15 |g month:01 |g pages:91-97 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.55563/clinexprheumatol/g8xqxr |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2021 |e 1 |b 15 |c 01 |h 91-97 | ||